<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776477</url>
  </required_header>
  <id_info>
    <org_study_id>NCCD20080101</org_study_id>
    <nct_id>NCT00776477</nct_id>
  </id_info>
  <brief_title>The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <brief_summary>
    <textblock>
      Clopidogrel is a antiplatelet agent and is effective at reducing intimal hyperplasia in
      animal models of thrombosis.Several large clinical trials have demonstrated that clopidogrel
      with aspirin can reduce ischemic events and mortality in patients with atherosclerotic
      disease,therefore the combination of two antiplatelets might be useful to prevent patients
      received coronary artery bypass graft surgery from Saphenous vein graft disease. the aim of
      this study is to estimate the safety and efficacy of clopidogrel and aspirin therapy versus
      aspirin alone in patients after CABG.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vein graft patency examined by CT scan</measure>
    <time_frame>three months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse coronary events Incidence of major bleeding events</measure>
    <time_frame>two years following surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel and aspirin</intervention_name>
    <description>clopidogrel 75mg daily and aspirin 100mg daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin 100mg daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts,
             with or without the use of cardiopulmonary bypass.

        Exclusion Criteria:

          -  Emergency surgery

          -  Valve surgery

          -  Redo CABG

          -  Left ventricle ejection fraction &lt; 30%

          -  Preoperative use of clopidogrel (with the exception of the current admission)

          -  Preoperative use of warfarin

          -  Allergy to aspirin or clopidogrel

          -  History of cerebrovascular accident

          -  History of severe liver disease

          -  Morbid obesity

          -  Current malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of cardiovascular diseases,Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ge gao, MD</last_name>
      <phone>8601088398244</phone>
      <email>docgaoge@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>shengshou hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>October 20, 2008</last_update_submitted>
  <last_update_submitted_qc>October 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>shengshou hu,MD</name_title>
    <organization>Institute of cardiovascular diseases&amp; Fuwai Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

